UCLA Radiology HHT Treatment Program Has Been Recognized Nationally as a Center of Excellence.
12/01/2010
The Hereditary Hemorrhagic Telangiectasia (HHT) program, co-directed by Drs. Justin McWilliams and Gary Duckwiler, is a multidisciplinary practice which facilitates the comprehensive coordination of care necessary for treating HHT patients.
HHT is an autosomal dominant vascular disorder affecting approximately 1 in 5000 people. HHT gene mutations lead to abnormal vascular structures, ranging from dilated microvessels (telangiectasia) to large arteriovenous malformations (AVMs).
Because of the rarity of the disease, and the need for coordinated treatment among specialists of different organ systems, the HHT Foundation has established several Centers of Excellence for HHT treatment. The UCLA Center of Excellence for HHT includes physician team members from 10 different subspecialties, and offers coordinated, knowledgeable care for HHT, including the full array of counseling, screening, diagnosis, and treatment.
Dr. McWilliams was featured on Nov. 26, 2010 in a KABC-Channel 7 story about a young girl being treated at Ronald Reagan UCLA Medical Center for HHT, a genetic disorder that produces abnormal blood vessels.
To learn more about the HHT Treatment Program, please visit HHT.ucla.edu.
